Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Cash from Investing Activities (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Cash from Investing Activities for 16 consecutive years, with $4.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 332.9% to $4.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.7 million, a 148.43% increase, with the full-year FY2024 number at -$3.7 million, up 84.95% from a year prior.
  • Cash from Investing Activities was $4.7 million for Q3 2025 at Xtant Medical Holdings, up from -$317000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $4.7 million in Q3 2025 to a low of -$17.4 million in Q1 2023.
  • A 5-year average of -$1.5 million and a median of -$483000.0 in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 4355.5% in 2023, then surged 332.9% in 2025.
  • Xtant Medical Holdings' Cash from Investing Activities stood at -$595000.0 in 2021, then grew by 29.08% to -$422000.0 in 2022, then crashed by 448.1% to -$2.3 million in 2023, then surged by 75.49% to -$567000.0 in 2024, then surged by 925.22% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Cash from Investing Activities are $4.7 million (Q3 2025), -$317000.0 (Q2 2025), and -$1.1 million (Q1 2025).